Biosmart Research

Biosmart Research

BioSmart Research: Nutraceutical CBD Isolates For Professional Distribution.


View on Wefunder
Security Type
Convertible Note
Min Investment
San Francisco, CA
Offering Date
June 30, 2021
Expected Close Date
April 30, 2022
Security Price

Use of Proceeds

  • ($50,000) 20% towards marketing expense, 7.5% towards WeFunder Fees, 40% to pay off existing equipment note, 20% to open a retail dispensary/distribution center, 12.5% for additional inventories, cash reserve and operating capital.
  • ($1,070,000) 10% Additional funds for high-speed labeling & packaging equipment, 20% additional dispensaries, 15% additional marketing expenses, 15% for additional payroll, 10% for legal, accounting, & taxes, 15% for inventories, 7.5% cash reserve and operating capital, 7.5% Wefunder fee


B Renee Searle, CEO
Renee has 40 years’ experience as an entrepreneur with 30 patents resulting in $60 MM in product sales. Her fields of research include biotechnology, electronics and cannabinoid research.

Research Reports

No reports have been submitted

Become a Reporter

Security Description

A convertible security is a security that can be converted into another security, typically equity in the next round of financing.

Key Deal Facts

Launch in 2019 produced $1.7M in sales
Biosmart produces pain management and anti-anxiety formulas for clinical and retail distribution
BioSmart has a 3-year technology lead using high-pressure liquid chromatography for isolate extraction
BioSmart markets through it's own retail dispensaries, healthcare providers, pharmacies, affiliates, and internet sales
U.S. Market for non-steroidal OTC pain relievers is $21.9 B/yr. US CBD market is $4.7 B/yr.
Clinical dosing levels with CBD isolates produce similar results to OTC pain relievers without the side effects.
BioSmart collaborates with university and clinical researchers and is a member of Choose Wisely, a patient forum
BioSmart Research represents a responsible approach to improving quality of life and advancing cannabinoid research